Stop solving the instance. Solve the pattern.
Patients eligible for CAR-T live too far from a certified treatment center. There are too few dementia specialists to diagnose early Alzheimer's disease. Insurance coverage for biomarker testing is inconsistent.
Each of these invites an obvious fix: build more centers, train more geriatricians, mandate coverage. Each fix is real, and each gets built one at a time, for one product or one disease — and is not carried forward to the next. The next innovation arrives, the same class of obstacle appears in new clothing, and the work starts over.
Traced to their root causes, these gaps turn out to be instances of a small number of readiness gap archetypes that recur across diseases and innovation types. Biomedical System Readiness identifies the archetype rather than the instance, so that what gets built is reusable.
The six archetypes:
Wrong Pocket Problem — Costs are borne by one actor while the savings accrue to another, or to society at large.
Seen in: durable cell and gene therapies, early detection in Alzheimer's disease, prevention broadly.
Pathway Discontinuity — Diagnostic capacity, workforce, and treatment infrastructure develop on unsynchronized timelines. The system identifies eligible patients faster than it can act on them.
Seen in: biomarker testing, CAR-T, anti-amyloid infusion with MRI monitoring.
Evidentiary Orphaning — The evidence decision-makers require is structurally impossible to generate given the disease or product. Innovations stall not on merit but on evidentiary form.
Seen in: rare disease, cell and gene therapy, pediatric oncology.
Broken Feedback Loop — The data needed to make or improve decisions exists, but sits behind legal uncertainty, incompatible standards, and siloed governance. The system cannot learn from its own experience.
Seen in: outcomes-based agreements, registries, longitudinal real-world evidence, post-market safety.
Accountability Vacuum — The work is well-specified and everyone agrees it should happen, but no actor's mandate, budget line, or job description contains it.
Seen in: care navigation, transitions of care, referral pathways, measurement infrastructure.
Practice Inertia — Capability, payment, and evidence are all in place, but workflow, incentives, and clinical routine have not moved. The binding constraint is behavioral and organizational.
Seen in: biosimilars, genomic-guided prescribing, guideline-concordant care.
Why archetypes change the economics
The same archetype turns up in cases with nothing clinical in common. The wrong pocket problem shapes both durable cell and gene therapy and early detection in Alzheimer's disease — different diseases, different products, same structure.
That repetition is what makes a solution portable. Address the instance and you have solved one problem for one product. Address the archetype and the design work carries forward, with the economies of scale that follow.
It also changes what has to be measured. If demonstration sites each measure something different, their evidence scatters instead of compounding and never reaches the threshold that moves policy. Working at the archetype level requires a shared measurement spine — which is what Biomedical Health Efficiency is built to provide.